Inclusion Criteria:

Only the patients who meet all these criteria can be enrolled in the study:

- Patients with prior histological confirmation of newly diagnosed primary glioblastoma
multiforme in supratentorial cerebral hemisphere.

- Gross total resection or partial resection (imaging) >70%.

- At least be capable to obtain a tissue sample for MGMT analysis during surgery.

- Chemo-radiotherapy to be expected from Week 5 (Day 29) after surgery.

- Age >=18 and <=70 years.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

- Life expectancy >=9 months.

- Laboratory test values must satisfy the following criteria:

- absolute neutrophil count >=1.5 x 10^9/L;

- platelet count >=100 x 10^9/L;

- hemoglobin >=80 g/L;

- blood urea nitrogen and creatinine < 1.5 x upper limit of normal value (ULN);

- total bilirubin and direct bilirubin < 1.5 x ULN;

- alanine aminotransferase and aspartate aminotransferase < 3 x ULN;

- alkaline phosphatase < 2 x ULN.

- Patients must be willing to provide written informed consent.

- Patients of child-bearing potential (including female subjects and the female
partners of male subjects) must use an effective method of contraception.

Exclusion Criteria:

Patients will not be enrolled if any of the following criteria apply:

- Patient with previous or current malignancies (except melanoma) at other sites,
unless disease free for at least 3 years.

- Patient who received chemotherapy, radiotherapy for study indication, or other
medications for antitumor indication prior to surgery.

- Patient with recurrent or multiple malignant glioma (including gliomatosis cerebri).

- Patient with metastatic lesions at the subtentorial or outside of calvaria.

- Patient who received chemotherapy or radiotherapy sensitizers for head or neck tumor.

- Patient who received radiotherapy at head or neck which leads to radiotherapy domain
overlapping.

- Patient with acute infections requiring intravenous antibiotics.

- Frequent vomiting or medical condition that could interfere with oral medication
intake (eg, partial bowel obstruction).

- Known human immunodeficiency virus (HIV)-positive or acquired immune deficiency
syndrome (AIDS)-related illness.

- Woman who is pregnant or breastfeeding.

- Patient with a history of hypersensitivity to temozolomide or other analogic
alkylating agents.

- Patient with any other conditions under which investigators think the subject is not
suitable for enrolment, such like having known that the subject may not have good
compliance.